-- US weekly ethanol production dropped slightly, according to the US Energy Information Administration report on Wednesday.
For the week ending April 24, US ethanol production averaged 1.01 million barrels per day, below 1.04 nnb/d last week and 1.04 mmb/d a year ago.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $398, 17.1x our new 2027 EPS estimate, above AMGN's 10-year historical forward average of 14.1x, justified by its strengthening outlook. We raise our 2026 EPS view to $22.56 from $22.15 and our 2027 EPS to $23.23 from $22.83. AMGN delivered a strong Q1, showcasing significant positive momentum across its business. The company's six core growth drivers generated $5.6 billion in the quarter, growing 24% Y/Y. Standout performers included Repatha, with 34% Y/Y sales growth and the rare disease drug Uplinza, which saw sales surge 188% Y/Y. In terms of pipeline advancement, we continue to view the developments on Amgen's obesity treatment candidate, MariTide, as encouraging. AMGN announced new Phase III trials to explore less frequent dosing schedules (every eight or 12 weeks), a key potential differentiator, in our view. MariTide's potential for monthly or even less frequent (quarterly) dosing could be an important differentiator that would improve patient convenience and long-term adherence.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target to $235 from $250, valuing shares at 19.5x our 2027 EPS outlook of $12.04 (adjusted from $12.03; 2026 EPS view revised to $11.26 from $11.25), a discount to ITW's long-term multiple average given a slowing rate of growth. Anemic growth and softness in several of ITW's segments were reflected in Q1 results. Organic sales grew just 0.4%, with a 1% headwind from product pruning activity and declines in four out of seven segments: Food Equipment -3%, Automotive OEM -1%, Construction Products -1%, and Specialty Products -5%. More positively, enterprise initiatives continue to drive margin gains, with pricing fending off inflationary pressures well. While management noted outperformance across challenged markets in Q1, we still view ITW as lagging behind other industrial peers that have a more concentrated exposure to secular growth opportunities. We reiterate our Sell recommendation on shares.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Following the recent pullback in shares and encouraging Q3 FY 26 (Jun.) results, we lift our 12-month target by $50 to $1,050 and upgrade our view on shares to Buy from Hold. We value shares at 30.5x our FY 27 EPS outlook of $34.42 (up from $33.35; FY 26 EPS view revised to $31.20 from $30.90), above the company's long-term multiple average given an accelerated growth trajectory within aerospace markets. PH's Diversified Industrial business is beginning to inflect into recovery, with orders above 7% in NA signaling a cyclical uptrend. Q3 structural improvements in margins inform our upgraded outlook for earnings in FY 26-FY 27, with negative mix impacts from outsized growth in lower-margin OEM products being more than offset by strong operational execution. With greater participation in growth across the portfolio, PH once again deploying capital to synergistic M&A, and margin expansion still in full swing, we believe that shares are positioned to outperform over the next 12 months.